Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Rebeca Bailen, Maria Jesus Pascual-Cascon, Manuel Guerreiro, Lucia Lopez Corra, Anabelle Chinea, Arancha Bermudez, Antonia Sampo, Inmaculada Heras, Estefania Garcia-Torres, Melissa Torres, Jose J. Rifon Roca, Beatriz Herruzo, Jaime Sanz, Marta Fonseca, Pilar Herrera, Mercedes Colorado, Leyre Bento, Oriana Lopez-Godino, Carmen Martin Calvo, Gillen Oarbeascoa, Jose L. Diez-Martin, Mi Kwon

BLOOD（2021）

Cited 5|Views15

No score

Abstract

Introduction: High-dose post transplant cyclophosphamide (PTCY) effectively prevents graft-versus-host disease (GVHD) after unmanipulated HLA-haploidentical hematopoietic stem cell transplant (HSCT) and offer low rates of GVHD in the setting of HLA identical transplant. The objective of our study was to compare the outcomes of haplo vs HLA identical HSCT in patients undergoing HSCT for acute myeloid leukemia (AML) using PTCY.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined